BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.
BEAT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Biotelemetry Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biotelemetry Inc ranked in the 94th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3682.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Biotelemetry Inc, consider:
Its compound free cash flow growth rate, as measured over the past 4.69 years, is 1.64% -- higher than 94.51% of stocks in our DCF forecasting set.
The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 20.29% of the free cash flow producing stocks we're observing.
As a business, Biotelemetry Inc experienced a tax rate of about 26% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 89.44% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
MNKKQ, RDY, ALPN, CORT, and FVE can be thought of as valuation peers to BEAT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Needham initiated BioTelemtry ([[BEAT]] +6.0%) with a Buy rating, price target of $52, indicating upside of 33% from current levels.Analyst David Saxon says that sales mix shift in Healthcare, the continued ramp of the company's Geneva Health Solutions remote monitoring, and the strong Research bookings should contribute to the company's...
DUBLIN--(BUSINESS WIRE)--The "Global Cardiac Safety Services Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global cardiac safety services market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of clinical trials, growing outsourcing of R&D services and increasing R&D investment coupled with pharmaceutical R&D across the globe. The growing R&D expenditure is also dri
Ladies and gentlemen, good afternoon, and thank you for joining us for the BioTelemetry Second Quarter 2020 Earnings Conference Call. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future, to be materially different from the statements that the company's executives may make today. It is now my pleasure to turn the floor over to your host, Mr. Joseph Capper, President and CEO of BioTelemetry.
Posts Strong Results and Ramps Up Business Development ActivityMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended June 30, 2020. Company Highlights * Recognized quarterly total revenue of $99.1 million * Total revenue declined 11.4% year-over-year due to the impact of COVID-19 across most of our businesses * Reported quarterly GAAP net income of $2.3 million, or 2.3% of total revenue * Realized quarterly adjusted EBITDA of $25.6 million, or 25.8% of total revenue * Acquired Remote Patient Monitoring (“RPM”) assets from a subsidiary of Centene Corporation * Entered...